Behavioral effects of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, (DOI) in the elevated plus-maze test.
E S Onaivi, C Bishop-Robinson, N A Darmani, E Sanders-Bush
Life Sciences November 17, 1995 DOI: 10.1016/0024-3205(95)02242-9 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal behavioral pharmacology experiment Peer reviewed |
|---|---|
| Population | Hooded rats, ICR mice, DBA/2 mice, and C57/BL6 mice |
| Interventions | DOI Mianserin Ketanserin Flumazenil |
| Dose | DOI 0.1-5.0 mg/kg (rats) and 0.1-2.0 mg/kg (mice); mianserin 0.5 mg/kg; ketanserin 0.1 mg/kg |
| Measures | plus-maze |
| Key findings | DOI produced aversion to open plus-maze arms at lower doses and anti-aversion at higher doses in hooded rats and ICR mice, with strain-dependent opposing effects in DBA/2 (aversion) and C57/BL6 (anti-aversion) mice. Mianserin and ketanserin blocked the anti-aversive behavior, but only mianserin reversed high-dose DOI aversion in ICR mice. The authors conclude that DOI-induced anxiolysis or anxiogenesis may not involve benzodiazepine receptors, since flumazenil was ineffective. |
Abstract
The serotonin (5-hydroxytryptamine, 5-HT) system has consistently been implicated in the actions of (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and other hallucinogens. Recent evidence suggest that the 5-HT2A/2C receptor subtypes may be major targets for such drugs in the CNS. DOI-treated hooded rats (0.1-5.0 mg/kg) and DOI treated ICR mice (0.1-2.0 mg/kg), displayed aversions at lower doses and anti-aversions at higher doses to the open arms of the plus-maze. Mianserin (0.5 mg/kg) and ketanserin (0.1 mg/kg) blocked the anti-aversive behavior, but only mianserin was effective at reversing the aversions produced by the higher doses of DOI in the ICR mice. DOI produced an intense aversion in the DBA/2 and anti-aversion in the C57/BL6 mice to the open arms of the plus-maze. These opposing actions of DOI in the plus-maze may be exploited in studying the neurobehavioral effects of hallucinogens. Since flumazenil was ineffective at blocking the DOI induced changes, it was concluded that the mechanism of DOI induced anxiolysis or anxiogenesis may not involve an action at the benzodiazepine receptors.
Citations in the library
Cited by 9
- Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states. Science November 15, 2024
- Ventral hippocampal parvalbumin interneurons gate the acute anxiolytic action of the serotonergic psychedelic DOI. Neuron November 20, 2024
- 1-(2,5-Dimethoxy-4-iodophenyl)-2-aminopropane (DOI): From an Obscure to Pivotal Member of the DOX Family of Serotonergic Psychedelic Agents - A Review. ACS Pharmacology & Translational Science June 14, 2024
- Psychedelics: A review of their effects on recalled aversive memories and fear/anxiety expression in rodents Neuroscience & Biobehavioral Reviews September 20, 2024
- Behavioral profiles in rats distinguish among "ecstasy," methamphetamine and 2,5-dimethoxy-4-iodoamphetamine: Mixed effects for "ecstasy" analogues. Behavioral Neuroscience October 1, 2010
and 4 more in the library
Cites 6
- Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents. Life Sciences December 17, 1984
- Adverse consequences of lysergic acid diethylamide Addiction October 1, 1993
- Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs. Psychopharmacology 1991
- Pharmacological characterization of cannabinoids in the elevated plus maze. Journal of Pharmacology and Experimental Therapeutics June 1, 1990
- A primate model for the study of hallucinogens. Pharmacology, Biochemistry, and Behavior February 1986
and 1 more in the library